Effect of octreotide on the size of a somatotroph adenoma before (A) and after 12 weeks (B) and 24 weeks (C) of treatment with short-acting octreotide

Reproduced with permission from: Bevan, JS, Atkin, SL, Atkinson, AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octeotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002: 87:4554. Copyright © 2002. The Endocrine Society.